Goldman Downgrades TEVA On Valuation
Analysts at Goldman Sachs downgrade Teva Pharmaceutical (NASDAQ: TEVA) from "conviction buy" to "buy." The target price for TEVA is set to $67.
According to Goldman Sachs, the downgrade in the rating is based on valuation.
TEVA’s shares lost 0.96% to $60.40. More Analyst Ratings here


























